Role of conservative breast surgery in locally advanced breast cancer after neoadjuvant chemotherapy
DOI:
https://doi.org/10.18203/2349-2902.isj20190092Keywords:
Conservative breast surgery, Locally advanced breast cancer, Neo-adjuvant chemotherapyAbstract
Background: Locally advanced breast cancer represents 20%-25% of breast cancer patients at diagnosis. The aim of this prospective study was to assess the feasibility and the oncologic outcome in the treatment of patients of locally advanced breast cancer that had been downstaged by neoadjuvant chemotherapy to the extent that makes them eligible for conservative breast surgery.
Methods: This prospective study was done on 50 female patients who were diagnosed with locally advanced breast cancer and received neoadjuvant chemotherapy to downstage cancer making it eligible for conservation, managed and treated at El Menoufia University Hospital and Tanta Cancer Center from March 2017 to March 2018 after applying inclusion and exclusion criteria. The collected data were organized, tabulated and statistically analyzed using SPSS software.
Results: Significant difference between pre and post-chemotherapy tumor size in patients with locally advanced breast cancer. Conservative breast surgery with intraoperative frozen section assured free margins in all of them with acceptable cosmetic outcome. No local recurrence recorded after one year of follow up.
Conclusions: In the present study, it was observed that conventional neoadjuvant chemotherapy is effective in downgrading the tumor size and axillary lymph nodes in patients with locally advanced breast cancer. Breast conservation after neoadjuvant chemotherapy is safe in terms of local recurrence.
Metrics
References
Kelly KH, John FRR. Breast. In: Schwartz’s Principles of Surgery. 10th ed. 2015; 497-546.
Giordano SH. Update on locally advanced breast cancer. Oncol. 2003;8(6):521-30.
Vergine M, Scipioni P, Garritano S, Colangelo M, Di Paolo A, Livadoti G, et al. Breast-conserving surgery after neoadjuvant chemotherapy in patients with locally advanced cancer: preliminary results. Giornale Chirurgia. 2013;34(9-10):254.
Franceschini G, Terribile D, Magno S, Fabbri C, Accetta C, Di Leone A, et al. Update on oncoplastic breast surgery. Eur Rev Med Pharmacol Sci. 2012;16(11):1530-40.
Mustonen P, Härmä M. Viewpoints on oncoplastic surgery in invasive breast cancer. Scandinavian J Surg. 2002;91(3):255-62.
Fan F. Evaluation and reporting of breast cancer after neoadjuvant chemotherapy. Open Pathol J. 2009;3(2):58-63.
Lee MC, Newman LA. Management of patients with locally advanced breast cancer. Surg Clin North Am. 2007;87(2):379-98.
Tewari M, Krishnamurthy A, Shukla HS. Breast conservation in locally advanced breast cancer in developing countries: wise or waste. Surg Oncol. 2009;18(1):3-13.
Barranger E, Antomarchi J, Chamorey E, Cavrot C, Flipo B, Follana P, et al. Effect of neoadjuvant chemotherapy on the surgical treatment of patients with locally advanced breast cancer requiring initial mastectomy. Clin Breast Cancer. 2015;15:e231-5.
Mashoori N, Zand S, Nazemian R, Kaviani A. Effect of the surgery type, mastectomy vs. breast conserving surgery, on outcomes of patients with locally advanced breast cancer receiving neoadjuvant therapy. Arch Breast Cancer. 2017;4(4):129-35.
Parmar V, Krishnamurthy A, Hawaldar R, Nadkarni MS, Sarin R, Chinoy R, et al. Breast conservation treatment in women with locally advanced breast cancer–experience from a single centre. Inter J Surg. 2006;4(2):106-14.
Sweeting RS, Klauber-DeMore N, Meyers MO, Deal AM, Burrows EM, Drobish AA, et al. Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate. Am Surg. 2011;77(7):850-5.
El-sayed MI, Maximous DW, Zakhary MM, Mikhail NN. Biological markers and response to neoadjuvant taxane-based chemotherapy in patients with locally advanced breast cancer. ISRN Oncol. 2012.
Shin HC, Han W, Moon HG, Im SA, Moon WK, Park IA, et al. Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients. Ann Surg Oncol. 2013;20(8):2582-9.
Salem MA, Hamza HA, Abd NM. Neoadjuvant chemotherapy and surgical options for locally-advanced breast cancer: a single institution experience. Middle East J Cancer. 2017;8:127-34.
Rahman MS, Akhter PS, Hasanuzzaman M, Rahman J, Bhattacharjee A, Rassell M, et al. Outcome of neoadjuvant chemotherapy in locally advanced breast cancer: a tertiary care center experience. Bangla Med J. 2016;45(3):141-6.
Costa SD, Loibl S, Kaufmann M, Zahm DM, Hilfrich J, Huober J, et al. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol. 2009;28(1):83-91.
Mittra I, Badwe RA, Dinshaw K, Sarin R, Chinoy RC, Nair R, et al. Conservative surgery in breast cancer. Ind J Surg. 2003;65(4):325-5.
Costa Vieira RA, Carrara GF, Neto CS, Morini MA, Brentani MM, Folgueira MA. The role of oncoplastic breast conserving treatment for locally advanced breast tumors. A matching case-control study. Ann Med Surg. 2016;10:61-8.
Ranisavljević M, Selaković V, Lukić D, Radovanović Z, Vicko F. Impact of neoadjuvant chemotherapy on wound complications after breast surgery. Arch Oncol. 2013;21(3-4):105-8.
Levy A, Borget I, Bahri M, Arnedos M, Rivin E, Vielh P, et al. Loco‐regional control after neo‐adjuvant chemotherapy and conservative treatment for locally advanced breast cancer patients. Breast J. 2014;20(4):381-7.